Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
E For L Aim PCLBKK:EFORL -8.33%25 3-Year EBITDA Growth Rate is -3.10% as of Jun. 2026. GuruFocus rates BKK:EFORL with a GF Score™ of 25/100 and a GF Value™ of ฿0.14 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 106 Medical Distribution companies, E For L Aim PCL ranks worse than 69.81% on this metric.
During the past 12 months, E For L Aim PCL's average EBITDA Per Share Growth Rate was -27.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -3.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of E For L Aim PCL was 110.00% per year. The lowest was -63.00% per year. And the median was 20.35% per year.
E For L Aim PCL (BKK:EFORL) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
E For L Aim PCL 3-Year EBITDA Growth Rate Related Terms
BKK:EFORL vs MCK, COR, CAH: 3-Year EBITDA Growth Rate Comparison
For the Medical Distribution subindustry, E For L Aim PCL's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
E For L Aim PCL 3-Year EBITDA Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, E For L Aim PCL's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where E For L Aim PCL's 3-Year EBITDA Growth Rate falls into.
E For L Aim PCL 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -3.10% mean?
E For L Aim PCL (BKK:EFORL) has a 3-Year EBITDA Growth Rate of -3.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for E For L Aim PCL and its competitors. According to the industry distribution chart, E For L Aim PCL ranks #74 out of 106 companies in the Medical Distribution industry, placing it in the top 69.8%.
Is E For L Aim PCL's 3-Year EBITDA Growth Rate too high?
E For L Aim PCL's current 3-Year EBITDA Growth Rate is -3.10%. Based on the distribution chart, E For L Aim PCL ranks #74 out of 106 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, E For L Aim PCL has a GF Score™ of 25/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does E For L Aim PCL's 3-Year EBITDA Growth Rate compare to MCK and COR?
According to the Medical Distribution industry distribution chart, E For L Aim PCL ranks #74 out of 106 companies for 3-Year EBITDA Growth Rate. This places E For L Aim PCL in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 6.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 6.15, based on 106 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for E For L Aim PCL and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 6.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. E For L Aim PCL's current 3-Year EBITDA Growth Rate is -3.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is E For L Aim PCL stock overvalued right now?
Based on GuruFocus' analysis, E For L Aim PCL (BKK:EFORL) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿0.14, compared to a current price of ฿0.11 — trading 21.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -3.10%. E For L Aim PCL's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For E For L Aim PCL (BKK:EFORL), the current 3-Year EBITDA Growth Rate is -3.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is E For L Aim PCL (BKK:EFORL) Overvalued in 2026?
Based on GuruFocus' analysis, E For L Aim PCL stock appears to be undervalued.
The current stock price of ฿0.11 is trading 21.4% below its estimated GF Value™ of ฿0.14.
GuruFocus considers E For L Aim PCL to be Modestly Undervalued.
Key valuation signals for BKK:EFORL:
3-Year EBITDA Growth Rate: -3.10%
GF Value™: ฿0.14 vs. price of ฿0.11 (21.4% below fair value)
No single metric tells the full story. See the BKK:EFORL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
E For L Aim PCL is engaged in the distribution of medical devices and equipment. The company and subsidiary have distributor agreements for medical devices and equipment with foreign companies. Its products include Patient Monitor System, Central Monitors System, Defibrillator, Automated External Defibrillator (AED), Electrocardiographs, Electroencephalogram (EEG), PSG System (Sleep Labs), and Accessories and Consumables. The group is principally engaged in one operating segment which is the distribution of medical device and equipment and providing service of medical equipment. Their operations are carried out in Thailand.
25GF Score
Get the complete analysis for BKK:EFORL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:EFORL has been successfully added to your 
